ArticleMaterials today. Bio2026
Therapeutic effects of hypoxia-preconditioned cartilage progenitor cell-exosomes on osteoarthritis through autophagy activation and macrophage polarization modulation.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immune dysregulation in osteoarthritis: Mechanisms, biomarkers, and therapeutic opportunities.Journal of translational autoimmunity · 2026Review
- Functionalized GelMA-based hydrogels for osteoimmunomodulation and bone regeneration.Frontiers in bioengineering and biotechnology · 2026Review
- Paradigm shift in macrophage polarization in osteoarthritis: from M1/M2 imbalance to macrophage state reprogramming in the ageing immune microenvironment.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a prevalent degenerative joint disease characterized by progressive cartilage loss, pain, and functional disability. While tissue engineering holds promise for cartilage repair, obtaining high-quality seed cells with optimized functional activity remains a bottleneck. Exosomes derived from cartilage progenitor cells (CPCs) have emerged as potent cell-free therapeutic candidates. Here, we demonstrate that exosomes from hypoxia-preconditioned CPCs (H-Exos) possess superior regenerative capabilities compared to their normoxic counterparts. specifically by promoting proliferation and migration while suppressing catabolism in IL-1β-treated ATDC5 cells. Mechanistically, we show that hypoxic preconditioning enriches miR-222-3p in H-Exos, which targets Rab1A to inhibit mTORC1 signaling and restore autophagy, thereby enhancing chondrocyte anabolism. Notably, we also identified a distinct immunomodulatory function: H-Exos were efficiently internalized by macrophages (RAW264.7), driving their polarization toward an anti-inflammatory phenotype via inhibition of the NF-κB signaling pathway. In a rat OA model, intra-articular delivery of a GelMA/H-Exos composite hydrogel significantly attenuated cartilage destruction and subchondral bone remodeling, concomitant with favorable modulation of synovial macrophage polarization. Collectively, this study elucidates a dual protective mechanism-involving the miR-222-3p-Rab1A-mTORC1-autophagy axis and macrophage reprogramming-and presents a promising biomaterial-based strategy for comprehensive OA therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.